CTX-130 (as an anti-CD70 CAR-T) has been tested in the COBALT-LYM (T-cell lymphoma) and COBALT-RCC (advanced clear cell renal cell carcinoma) studies. This evidence concerns the gene CD70 and clear cell renal carcinoma.